As The Beatles once sang, we all need a little bit of help from our friends. So, according to Reuters, it might not come as a huge surprise if U.S. drug giant Pfizer (PFE) uses its connections with President Trump to win an $8.5 billion bidding war with Danish rival Novo Nordisk (NVO) over obesity-fighting biotech Metsera (MTSR). Elevate Your …
Read More »
Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.45. LONDON — A bidding war has broken into the open for obesity-focused Metsera, with Novo Nordisk on Thursday saying it had made an offer for the biotech, a month after Pfizer announced its plan to purchase the firm. The Novo offer, …
Read More »Novo Nordisk Seeks to Outmuscle Pfizer With $9 Billion Bid for Metsera The Wall Street Journal European markets negative; Novo Nordisk drops 3% after surprise bid for Metsera CNBC Novo Nordisk bid for obesity-focused biotech firm could gazump Pfizer offer The Guardian Novo Offers $6.5 Billion for Metsera to Challenge Pfizer Bloomberg.com Metsera says Novo Nordisk’s $9B buyout offer “superior”; Pfizer calls bid “illusory” …
Read More »Novo Nordisk enters bidding war with Pfizer over US biotech Metsera Reuters Novo Nordisk launches bidding war with Pfizer for obesity drugmaker Metsera Yahoo Finance Novo Offers $6.5 Billion for Metsera to Challenge Pfizer Bloomberg Novo Nordisk hijacks Pfizer with bid for U.S. biotech Metsera CNBC Novo Nordisk submits proposal to acquire Metsera, Inc. GlobeNewswire Source link
Read More »
The logos of Danish drugmaker Novo Nordisk, maker of the blockbuster diabetes and weight-loss treatments Ozempic and Wegovy is seen outside theri building as the company presents the annual report at Novo Nordisk in Bagsvaerd, Denmark, on February 5, 2025. Mads Claus Rasmussen | Afp | Getty Images Several Novo Nordisk board members will step down from their positions after …
Read More »Weekly Stock Market Update: Apple, Taiwan Semiconductor and Novo Nordisk TheStreet The Week That Was, The Week Ahead: Macro & Markets, October 19, 2025 TipRanks Week ahead: Reflexivity meets reality FXStreet MarketBeat Week in Review – 10/13 – 10/17 TradingView This Week in Review | Q3 Earnings, US–China, Bull Market Turns 3, Gov’t Shutdown Fisher Investments Source link
Read More »
The ‘Barron’s Roundtable’ panelists discuss dividend stocks and reveal their stock picks. The price of Novo Nordisk’s blockbuster diabetes and weight loss-related drug Ozempic will be cut, according to President Donald Trump. Trump said this week during a White House event on fertility treatments and drug pricing the price reduction will come after swift negotiations with the drugmaker. “They’ll be …
Read More »Eli Lilly, Novo Nordisk Stocks Drop. Trump Targets Ozempic, ‘Fat Loss’ Drug Prices. Barron’s Novo Nordisk Shares Fall as Trump Moves to Cut Price of Weight-Loss Drugs The Wall Street Journal Trump says Ozempic prices will be ‘much lower’ for Americans Fox Business Eli Lilly and Novo Nordisk stocks fall as Trump says he wants $150 price for GLP-1s CNBC Novo, Lilly Fall as …
Read More »Novo Nordisk, Eli Lilly shares drop as Trump vows weight-loss drug price cuts Reuters Trump says Ozempic will get cheaper. Novo Nordisk, Eli Lilly stock slump qz.com Trump says price of Ozempic will be lowered Reuters Novo Nordisk shares slide as Donald Trump vows to cut Ozempic price Financial Times Trump: Cost of Ozempic Could Be $150. Dr. Oz: Not Yet. The Wall Street Journal …
Read More »Novo Nordisk to Acquire Akero Therapeutics for Up to $5.2 Billion The Wall Street Journal Novo Nordisk to buy Akero for up to $5.2 billion in new CEO’s revival push CNBC Novo CEO Says Risk-Taking, Deals Are Needed to Win Obesity Race Bloomberg.com Novo Nordisk Is Buying Akero Therapeutics. It’s More Good News for Biotech Stocks. Barron’s Novo buying Akero and its MASH hopeful …
Read More »